These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

914 related articles for article (PubMed ID: 28423515)

  • 1. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
    Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA
    Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the PI3K pathway in the brain--efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier.
    Salphati L; Heffron TP; Alicke B; Nishimura M; Barck K; Carano RA; Cheong J; Edgar KA; Greve J; Kharbanda S; Koeppen H; Lau S; Lee LB; Pang J; Plise EG; Pokorny JL; Reslan HB; Sarkaria JN; Wallin JJ; Zhang X; Gould SE; Olivero AG; Phillips HS
    Clin Cancer Res; 2012 Nov; 18(22):6239-48. PubMed ID: 22992516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells.
    Shingu T; Holmes L; Henry V; Wang Q; Latha K; Gururaj AE; Gibson LA; Doucette T; Lang FF; Rao G; Yuan L; Sulman EP; Farrell NP; Priebe W; Hess KR; Wang YA; Hu J; Bögler O
    J Transl Med; 2016 Feb; 14():46. PubMed ID: 26861698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
    Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
    Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human Glioblastoma.
    Salphati L; Alicke B; Heffron TP; Shahidi-Latham S; Nishimura M; Cao T; Carano RA; Cheong J; Greve J; Koeppen H; Lau S; Lee LB; Nannini-Pepe M; Pang J; Plise EG; Quiason C; Rangell L; Zhang X; Gould SE; Phillips HS; Olivero AG
    Drug Metab Dispos; 2016 Dec; 44(12):1881-1889. PubMed ID: 27638506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
    Spoerke JM; O'Brien C; Huw L; Koeppen H; Fridlyand J; Brachmann RK; Haverty PM; Pandita A; Mohan S; Sampath D; Friedman LS; Ross L; Hampton GM; Amler LC; Shames DS; Lackner MR
    Clin Cancer Res; 2012 Dec; 18(24):6771-83. PubMed ID: 23136191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PTEN reconstitution alters glioma responses to c-Met pathway inhibition.
    Goodwin CR; Lal B; Ho S; Woodard CL; Zhou X; Taeger A; Xia S; Laterra J
    Anticancer Drugs; 2011 Oct; 22(9):905-12. PubMed ID: 21654317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma.
    Wu S; Wang S; Zheng S; Verhaak R; Koul D; Yung WK
    Mol Cancer Ther; 2016 Jul; 15(7):1656-68. PubMed ID: 27196759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combinatorial therapy with adenoviral-mediated PTEN and a PI3K inhibitor suppresses malignant glioma cell growth in vitro and in vivo by regulating the PI3K/AKT signaling pathway.
    Nan Y; Guo L; Song Y; Wang L; Yu K; Huang Q; Zhong Y
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1477-1487. PubMed ID: 28401302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI3K-mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models.
    Lin F; de Gooijer MC; Hanekamp D; Chandrasekaran G; Buil LC; Thota N; Sparidans RW; Beijnen JH; Würdinger T; van Tellingen O
    Clin Cancer Res; 2017 Mar; 23(5):1286-1298. PubMed ID: 27553832
    [No Abstract]   [Full Text] [Related]  

  • 13. PARP targeting counteracts gliomagenesis through induction of mitotic catastrophe and aggravation of deficiency in homologous recombination in PTEN-mutant glioma.
    Majuelos-Melguizo J; Rodríguez MI; López-Jiménez L; Rodríguez-Vargas JM; Martí Martín-Consuegra JM; Serrano-Sáenz S; Gavard J; de Almodóvar JM; Oliver FJ
    Oncotarget; 2015 Mar; 6(7):4790-803. PubMed ID: 25576921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.
    Mallon R; Feldberg LR; Lucas J; Chaudhary I; Dehnhardt C; Santos ED; Chen Z; dos Santos O; Ayral-Kaloustian S; Venkatesan A; Hollander I
    Clin Cancer Res; 2011 May; 17(10):3193-203. PubMed ID: 21325073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.
    Philip CA; Laskov I; Beauchamp MC; Marques M; Amin O; Bitharas J; Kessous R; Kogan L; Baloch T; Gotlieb WH; Yasmeen A
    BMC Cancer; 2017 Sep; 17(1):638. PubMed ID: 28886696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
    Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice.
    Dai C; Zhang B; Liu X; Ma S; Yang Y; Yao Y; Feng M; Bao X; Li G; Wang J; Guo K; Ma W; Xing B; Lian W; Xiao J; Cai F; Zhang H; Wang R
    Endocrinology; 2013 Mar; 154(3):1247-59. PubMed ID: 23384836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
    García-García C; Rivas MA; Ibrahim YH; Calvo MT; Gris-Oliver A; Rodríguez O; Grueso J; Antón P; Guzmán M; Aura C; Nuciforo P; Jessen K; Argilés G; Dienstmann R; Bertotti A; Trusolino L; Matito J; Vivancos A; Chicote I; Palmer HG; Tabernero J; Scaltriti M; Baselga J; Serra V
    Clin Cancer Res; 2015 Dec; 21(24):5499-5510. PubMed ID: 26272063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.
    Kashiyama T; Oda K; Ikeda Y; Shiose Y; Hirota Y; Inaba K; Makii C; Kurikawa R; Miyasaka A; Koso T; Fukuda T; Tanikawa M; Shoji K; Sone K; Arimoto T; Wada-Hiraike O; Kawana K; Nakagawa S; Matsuda K; McCormick F; Aburatani H; Yano T; Osuga Y; Fujii T
    PLoS One; 2014; 9(2):e87220. PubMed ID: 24504419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor activity of dual inhibition of phosphatidylinositol 3-kinase and MDM2 against clear cell ovarian carcinoma.
    Makii C; Ikeda Y; Oda K; Uehara Y; Nishijima A; Koso T; Kawata Y; Kashiyama T; Miyasaka A; Sone K; Tanikawa M; Tsuruga T; Mori-Uchino M; Nagasaka K; Matsumoto Y; Wada-Hiraike O; Kawana K; Hasegawa K; Fujiwara K; Aburatani H; Osuga Y; Fujii T
    Gynecol Oncol; 2019 Nov; 155(2):331-339. PubMed ID: 31493899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.